EUVIMEDEUVIMED entdecken
Crossref

Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database

Hiroaki Ohta, Takeshi Horii, Takeo Yasu

Oncology · 2023

DOI: 10.1159/000533539 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2023. Verfasst von Hiroaki Ohta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Kiyose, Japan. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Carcinoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anamorelin is the first drug approved for the treatment of cancer cachexia, a debilitating condition characterized by weight loss, anorexia, and muscle mass depletion. Cachexia negatively affects a patient’s quality of life, survival, and response to chemotherapy. Studies describing anamorelin use are currently limited to a small number of pancreatic cancer cases.

Objectives

We aimed to examine the incidence and risk factors of adverse metabolic effects on glucose levels in cachexia patients with various carcinomas treated with anamorelin.

Method

We used real-world data of patients who received anamorelin between August 2021 and July 2022 and were registered in the JMDC claims database. We investigated the impact of metabolic adverse effects on glucose in patients receiving anamorelin with respect to the following factors: sex (male), age (>75 years), types of carcinoma, history of diabetes mellitus (DM), and concomitant use of steroids.

Results

The incidence of adverse metabolic effects on glucose was 12.3%, and pancreatic cancer and history of DM were associated with adverse metabolic effects on glucose. The median onset of adverse metabolic effects on glucose was 17 days after anamorelin treatment.

Conclusions

This study highlights the need to monitor and manage hyperglycemia in cachexia patients receiving anamorelin, especially in those with pancreatic cancer and a history of DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsCarcinomaPancreatic NeoplasmsHumansMaleAgedCachexiaGlucoseQuality of LifeJapanHydrazinesOligopeptides

Stichwörter der Autor:innen

AnamorelinCancer cachexiaCarcinomaDiabetes mellitus

Substanzen

GlucoseanamorelinHydrazinesOligopeptides

Autor:innen und Institutionen

  • Department of Medicinal Therapy Research, Pharmaceutical Education and Research Center, Meiji Pharmaceutical University, Kiyose, Japan.
  • Department of Pharmacy, Faculty of Pharmacy, Musashino University, Nishitokyo, Japan.

Zitieren

APA

Ohta, H., Horii, T., & Yasu, T. (2023). Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database. Oncology. https://doi.org/10.1159/000533539

Vancouver

Ohta H, Horii T, Yasu T. Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database. Oncology. 2023. doi:10.1159/000533539

BibTeX
@article{Ohta2023,
  author = {Ohta, Hiroaki and Horii, Takeshi and Yasu, Takeo},
  title = {Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database},
  journal = {Oncology},
  year = {2023},
  doi = {10.1159/000533539}
}
Kostenlos starten →